Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the moving parts behind a global derivatives powerhouse can feel overwhelming. CME Group’s annual reports stretch past 200 pages, and its Form 4 insider notices drop without warning—often right before rate-sensitive futures rallies. If you have ever asked, “Where can I find CME Group’s quarterly earnings report 10-Q filing?” or “How do I decode clearinghouse risk in the 10-K?”, you are not alone.
Stock Titan solves this complexity. Our AI-powered summaries turn dense disclosures into plain-English briefs—so understanding CME Group SEC documents with AI becomes routine. Need CME Group insider trading Form 4 transactions? We stream CME Group Form 4 insider transactions real-time, flagging executive stock transactions the moment they reach EDGAR. Looking for revenue per contract or margin requirements? The platform highlights them automatically within the CME Group annual report 10-K simplified, while our dashboard links every footnote to the relevant accounting rule.
You will find every filing type—10-K, 10-Q, 8-K, DEF 14A, S-8—indexed and searchable. Click the 10-Q tab for a concise CME Group earnings report filing analysis; open any 8-K for CME Group 8-K material events explained in seconds. The proxy section answers, “What’s inside the CME Group proxy statement executive compensation?” by extracting pay ratio, incentive targets, and peer comparisons. Real-time alerts keep you ahead when material events hit or when directors buy shares. Whether you monitor fee trends, hedge fund positioning, or just want CME Group SEC filings explained simply, Stock Titan provides the clarity professionals need—all in one place.
CME Group Inc. officer Derek Louis Sammann, Senior Managing Director and Global Head of Commodities Markets, reported several transactions in CME Class A common stock. On November 6, 2025, he transferred 2,300 shares at a stated price of $0, reducing his direct holdings to 8,683 shares and increasing the holdings of his revocable living trust to 16,914 shares, reflecting an internal ownership reorganization.
On November 20, 2025, the trust sold 5,886 shares at $275.65 per share, leaving the trust with 11,028 shares. On the same date, Sammann’s spouse sold 1,314 shares at $275.74 per share, leaving 7,022 shares held by the spouse. These trades update disclosed indirect ownership positions through both the trust and spouse.
CME Group (CME) insider transaction: Officer Hilda Harris Piell, Sr MD & Chief HR Officer, reported a Code G gift of 973 Class A common shares on 11/07/2025 at a reported price of $0. Following the transaction, she beneficially owns 29,418 shares, held directly.
The filing notes the shares were gifted to her donor advised fund. This is a charitable transfer rather than a market sale.
CME Group Inc. (CME) reported an insider transaction: Director Harold Ford Jr. sold 1,000 Class A shares on November 3, 2025, coded S (open market sale). The weighted average sale price was $263.53, with a price range of $263.21–$263.68.
Following the sale, he directly owns 1,091 shares. The company notes prices within a $1 range were aggregated and maintains detailed records available upon request.
CME Group Inc. reported Q3 2025 results with total revenue of
Market data and information services grew to
Year‑to‑date, operating cash flow reached
CME Group Inc. furnished an 8-K announcing quarterly results. The company reported that a press release dated October 22, 2025, covering financial results for the quarter ended September 30, 2025, was furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
The press release includes non-GAAP measures—revenues, expenses, operating income, net income, and earnings per share—with reconciliations to the most comparable GAAP metrics pursuant to Regulation G. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act.
Jonathan L. Marcus, Senior Managing Director and General Counsel at CME Group Inc. (CME), reported a sale of 392 shares of Class A common stock on 09/18/2025 at a reported price of $262 per share. The filing shows the transaction was executed under a Rule 10b5-1 trading plan adopted on February 18, 2025. After this sale the reporting person beneficially owns 7,851 shares of Class A common stock. The Form 4 is singularly filed for one reporting person and was signed by Margaret Austin Wright on behalf of Jonathan L. Marcus.
Form 144 notice for CME Group Inc. (CME) shows a proposed sale of 392 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $102,704.00 and an approximate sale date of 09/18/2025 on NASDAQ. The securities were acquired from the issuer as restricted stock on 09/16/2025 and payment was recorded as 09/16/2025. The filing also reports prior transactions: the person for whose account the sale is filed sold 376 shares on 09/16/2025 for gross proceeds of $97,368.96. The filing includes the required representation that the signer does not possess undisclosed material adverse information.
Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME), reported share transactions on Form 4 tied to restricted stock vesting. On 09/15/2025 he surrendered 1,117 Class A shares at $258.83 per share to satisfy tax withholding and later received 3,044 shares at the same price, leaving him with 19,367 Class A shares after that trade. On 09/16/2025 he surrendered 379 Class A shares at $259.83 for tax withholding, resulting in 18,988 shares held. The filing is signed on behalf of Mr. Cutinho on 09/17/2025 and lists these transactions as related to vesting and tax obligations.
Julie Winkler, Senior Managing Director and Chief Commercial Officer at CME Group (CME), reported insider transactions related to restricted stock vesting and tax-withholding on September 15-16, 2025. On 09/15/2025 she surrendered 1,081 shares at $258.83 to satisfy tax withholding upon vesting and received 3,044 shares at $258.83 from the vesting event, and on 09/16/2025 she surrendered 379 shares at $259.83 for tax withholding. After these transactions she beneficially owned 25,512 Class A shares. The Form 4 was signed on behalf of Ms. Winkler by Margaret Austin Wright on 09/17/2025. The filing shows routine equity vesting and share-withholding to cover taxes; no derivative transactions or additional compensatory arrangements are disclosed in this Form 4.
Kendal L. Vroman, Chief Transformation Officer of CME Group Inc. (CME), reported insider transactions on a Form 4 showing restricted stock vesting and related tax withholding. On 09/15/2025 he surrendered 971 Class A shares to the company at a reported price of $258.83 to satisfy tax withholding and, on the same day, was recorded as acquiring 2,608 Class A shares at $258.83, bringing his beneficial ownership to 20,395 shares. On 09/16/2025 he surrendered an additional 325 Class A shares at $259.83, leaving 20,070 shares reported as beneficially owned. The form states the surrenders were to fulfill tax withholding obligations upon vesting of restricted stock.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
